Lipid Management in Chronic Kidney Disease: Systematic Review of PCSK9 Targeting
Published 2018 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Lipid Management in Chronic Kidney Disease: Systematic Review of PCSK9 Targeting
Authors
Keywords
-
Journal
DRUGS
Volume 78, Issue 2, Pages 215-229
Publisher
Springer Nature
Online
2018-01-04
DOI
10.1007/s40265-017-0858-2
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Anti-PCSK9 antibodies for hypercholesterolaemia: Overview of clinical data and implications for primary care
- (2017) Olivier S. Descamps et al. INTERNATIONAL JOURNAL OF CLINICAL PRACTICE
- Pro-protein subtilisin kexin-9 (PCSK9) inhibition in practice: lipid clinic experience in 2 contrasting UK centres
- (2017) Monika Kohli et al. INTERNATIONAL JOURNAL OF CLINICAL PRACTICE
- A Highly Durable RNAi Therapeutic Inhibitor of PCSK9
- (2017) Kevin Fitzgerald et al. NEW ENGLAND JOURNAL OF MEDICINE
- Heparan sulfate proteoglycans present PCSK9 to the LDL receptor
- (2017) Camilla Gustafsen et al. Nature Communications
- Selective stalling of human translation through small-molecule engagement of the ribosome nascent chain
- (2017) Nathanael G. Lintner et al. PLOS BIOLOGY
- The Role of Proprotein Convertase Subtilisin/Kexin Type 9 in Nephrotic Syndrome-Associated HypercholesterolemiaClinical Perspective
- (2016) Mary E. Haas et al. CIRCULATION
- Circulating Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Predicts Future Risk of Cardiovascular Events Independently of Established Risk FactorsCLINICAL PERSPECTIVE
- (2016) Karin Leander et al. CIRCULATION
- PCSK9 in diabetic kidney disease
- (2016) Usama Elewa et al. EUROPEAN JOURNAL OF CLINICAL INVESTIGATION
- Efficacy of alirocumab in high cardiovascular risk populations with or without heterozygous familial hypercholesterolemia: Pooled analysis of eight ODYSSEY Phase 3 clinical program trials
- (2016) Michel Farnier et al. INTERNATIONAL JOURNAL OF CARDIOLOGY
- Variation in PCSK9 and HMGCR and Risk of Cardiovascular Disease and Diabetes
- (2016) Brian A. Ference et al. NEW ENGLAND JOURNAL OF MEDICINE
- Relationship Between Low‐Density Lipoprotein Cholesterol, Free Proprotein Convertase Subtilisin/Kexin Type 9, and Alirocumab Levels After Different Lipid‐Lowering Strategies
- (2016) Jacques Rey et al. Journal of the American Heart Association
- Efficacy and safety of the proprotein convertase subtilisin/kexin type 9 inhibitor alirocumab among high cardiovascular risk patients on maximally tolerated statin therapy: The ODYSSEY COMBO I study
- (2015) Dean J. Kereiakes et al. AMERICAN HEART JOURNAL
- Efficacy and safety of alirocumab in high cardiovascular risk patients with inadequately controlled hypercholesterolaemia on maximally tolerated doses of statins: the ODYSSEY COMBO II randomized controlled trial
- (2015) Christopher P. Cannon et al. EUROPEAN HEART JOURNAL
- Efficacy and Safety of Alirocumab in Reducing Lipids and Cardiovascular Events
- (2015) Jennifer G. Robinson et al. NEW ENGLAND JOURNAL OF MEDICINE
- Safety and efficacy of alirocumab 150 mg every 2 weeks, a fully human proprotein convertase subtilisin/kexin type 9 monoclonal antibody: A Phase II pooled analysis
- (2015) Michael J. Koren et al. POSTGRADUATE MEDICINE
- Relation of atherogenic lipoproteins with estimated glomerular filtration rate decline: a longitudinal study
- (2015) Jennie Lin et al. BMC Nephrology
- Effect of alirocumab, a monoclonal antibody to PCSK9, on long-term cardiovascular outcomes following acute coronary syndromes: Rationale and design of the ODYSSEY Outcomes trial
- (2014) Gregory G. Schwartz et al. AMERICAN HEART JOURNAL
- Statin Intolerance
- (2014) Zahid Ahmad AMERICAN JOURNAL OF CARDIOLOGY
- Elevated Circulating PCSK-9 Concentration in Renal Failure Patients is Corrected by Renal Replacement Therapy
- (2014) Marcin Konarzewski et al. AMERICAN JOURNAL OF NEPHROLOGY
- Chronic kidney disease on hemodialysis is associated with decreased serum PCSK9 levels
- (2014) H. Abujrad et al. ATHEROSCLEROSIS
- Efficacy and safety of evolocumab (AMG 145), a fully human monoclonal antibody to PCSK9, in hyperlipidaemic patients on various background lipid therapies: pooled analysis of 1359 patients in four phase 2 trials
- (2014) E. A. Stein et al. EUROPEAN HEART JOURNAL
- Cardiovascular disease in Europe 2014: epidemiological update
- (2014) Melanie Nichols et al. EUROPEAN HEART JOURNAL
- Looking into the Crystal Ball—Upcoming Drugs for Dyslipidemia
- (2014) Melvin George et al. JOURNAL OF CARDIOVASCULAR PHARMACOLOGY AND THERAPEUTICS
- Anti-PCSK9 Monotherapy for Hypercholesterolemia
- (2014) Michael J. Koren et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- KDIGO Clinical Practice Guideline for Lipid Management in CKD: summary of recommendation statements and clinical approach to the patient
- (2014) Christoph Wanner et al. KIDNEY INTERNATIONAL
- Plasma Lipoprotein(a) Levels Are Associated with Mild Renal Impairment in Type 2 Diabetics Independent of Albuminuria
- (2014) Jennie Lin et al. PLoS One
- Risk prediction with proprotein convertase subtilisin/kexin type 9 (PCSK9) in patients with stable coronary disease on statin treatment
- (2014) Christian Werner et al. VASCULAR PHARMACOLOGY
- Lipoprotein(a) Concentrations, Rosuvastatin Therapy, and Residual Vascular Risk
- (2013) Amit V. Khera et al. CIRCULATION
- Relationship of Apolipoproteins A-1 and B, and Lipoprotein(a) to Cardiovascular Outcomes
- (2013) John J. Albers et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Role of PCSK9 and IDOL in the pathogenesis of acquired LDL receptor deficiency and hypercholesterolemia in nephrotic syndrome
- (2013) S. Liu et al. NEPHROLOGY DIALYSIS TRANSPLANTATION
- Evaluation of cardiovascular disease burden and therapeutic goal attainment in US adults with chronic kidney disease: an analysis of national health and nutritional examination survey data, 2001–2010
- (2013) Andreas Kuznik et al. BMC Nephrology
- Chronic Kidney Disease as a Coronary Artery Disease Risk Equivalent
- (2013) Alexandrios Briasoulis et al. Current Cardiology Reports
- Rosuvastatin, Proprotein Convertase Subtilisin/Kexin Type 9 Concentrations, and LDL Cholesterol Response: the JUPITER Trial
- (2011) Z. Awan et al. CLINICAL CHEMISTRY
- Niacin: The Evidence, Clinical Use, and Future Directions
- (2011) Todd C. Villines et al. Current Atherosclerosis Reports
- The Peripheral Arterial disease study (PERART/ARTPER): prevalence and risk factors in the general population
- (2010) María Teresa Alzamora et al. BMC PUBLIC HEALTH
- Lipoprotein(a) as a cardiovascular risk factor: current status
- (2010) Børge G. Nordestgaard et al. EUROPEAN HEART JOURNAL
- Strong induction of PCSK9 gene expression through HNF1α and SREBP2: mechanism for the resistance to LDL-cholesterol lowering effect of statins in dyslipidemic hamsters
- (2010) Bin Dong et al. JOURNAL OF LIPID RESEARCH
- Major Lipids, Apolipoproteins, and Risk of Vascular Disease
- (2009) The Emerging Risk Factors Collaboration* JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Genetic and Metabolic Determinants of Plasma PCSK9 Levels
- (2009) Susan G. Lakoski et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Effect of statins on HDL-C: a complex process unrelated to changes in LDL-C: analysis of the VOYAGER Database
- (2009) Philip J. Barter et al. JOURNAL OF LIPID RESEARCH
- Plasma PCSK9 Concentrations Correlate with LDL and Total Cholesterol in Diabetic Patients and Are Decreased by Fenofibrate Treatment
- (2008) G. Lambert et al. CLINICAL CHEMISTRY
- Plasma PCSK9 levels are significantly modified by statins and fibrates in humans
- (2008) Janice Mayne et al. Lipids in Health and Disease
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search